Zepbound is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to help with weight management for adults who have a body mass index (BMI) score in the obese range, in conjunction with a reduced-calorie diet and increased physical activity. Zepbound may also be prescribed for adults with a BMI in the overweight range who have another health condition commonly correlated with higher body weight, including high blood pressure, type 2 diabetes, sleep apnea, or heart disease. Zepbound is also known by its drug name, tirzepatide.
Zepbound is a class of drugs known as glucagon-like peptide-1 (GLP-1) agonists. The drugs are believed to work by increasing insulin production, slowing the movement of food through the stomach, and producing feelings of fullness.
How do I take it?
Zepbound is given as a subcutaneous injection once per week. The dose gradually increases over several weeks. Your doctor will explain the correct dosing schedule.
The FDA prescribing information for Zepbound lists common side effects such as nausea, diarrhea, vomiting, constipation, pain in the abdomen, fatigue, injection site reactions, hair loss, belching, and gastroesophageal reflux disease.
Rare but serious side effects include thyroid C-cell tumors, severe gastrointestinal disease, kidney injury, gallbladder disease, pancreatitis, hypoglycemia, hypersensitivity reactions, complications with managing type 2 diabetes, and suicidal behavior.
For more information on this treatment, visit:
Zepbound — Eli Lilly
FDA Approves New Medication for Chronic Weight Management — U.S. Food and Drug Administration